Development and manufacture of drug-coated balloon catheters (DCB) and drug-eluting stents (DES)
CARDIONOVUM GmbH
BonnNew on Amplifa
About Cardionovum
CARDIONOVUM GmbH is a medical technology company based in Bonn that develops, manufactures and distributes medical products for the treatment of cardiovascular and intravascular diseases. The product range comprises coated balloon catheters (Drug Coated Balloons, DCB) for coronary and peripheral vascular intervention as well as drug-eluting coronary stents (DES). The DCB products are based on the company's proprietary SAFEPAX® paclitaxel coating matrix, complemented by a next-generation Amorphous Coating technology; in the stent segment, the sirolimus-eluting XLIMUS® system is offered. Applications include, among others, lesions of the superficial femoral artery, below-the-knee lesions, dialysis catheter stenoses and coronary in-stent restenoses. The company maintains an ongoing clinical study and post-marketing program for its products and is a member of the German Medical Technology Association (BVMed). In fiscal year 2024, the company generated revenue of around 21.6 million euros with 23 employees.
- Site
- Bonn
- Processes
- Manufacturing of coated balloon catheters (DCB - Drug Coated Balloons) with, Manufacturing of drug-eluting stents (DES - Sirolimus Eluting Coronary Stent System), Development, manufacturing and distribution of medical technology products for the treatment of, Amorphous Coating (next-generation balloon drug coating technology), Development of medical devices (DCB/DES), Manufacturing of medical devices, Distribution of medical devices, Clinical study and post-marketing program
- Materials
- Paclitaxel, Sirolimus, Paclitaxel coating matrix, Amorphous Coating
- Founded
- 2005-11-30
- Employees
- 23
- Industries
- Medical technology, Interventional cardiology, Peripheral vascular intervention, Cardiovascular therapies
- 01
Development of medical devices (DCB/DES)
- 02
Manufacturing including coating technology (SAFEPAX)
- 03
Clinical study and post-marketing program
- 04
Sales and marketing
Materials and Coating Technologies
Paclitaxel coating matrix
Coating technology for Drug Coated Balloons with low wash-off rates, among other things for peripheral and coronary balloon catheters.
Amorphous Coating
Next-generation balloon drug coating technology based on paclitaxel.
Sirolimus
Active ingredient of the drug-eluting coronary stent system XLIMUS®.
Locations
Bonn
DEHeadquarters: development, manufacturing and sales
- Materials
- Paclitaxel, Sirolimus
Products
Inside the production
Industries
Processes & technical limits
| Processes | Tolerance | Max. part | Weight | Lot size | Materials |
|---|---|---|---|---|---|
| Manufacturing of coated balloon catheters (DCB - Drug Coated Balloons) withSurface | – | – | – | – | Paclitaxel |
| Manufacturing of drug-eluting stents (DES - Sirolimus Eluting Coronary Stent System)Assembly | – | – | – | – | Sirolimus |
| Development, manufacturing and distribution of medical technology products for the treatment ofEngineering | – | – | – | – | – |
| Amorphous Coating (next-generation balloon drug coating technology)Surface | – | – | – | – | Paclitaxel |
Additional services
History
- 2005
Company registered on 30.11.2005 with its seat in Bonn, originally as 'MSO - GmbH Michael Orlowski'.
- 2010
Renamed CARDIONOVUM GmbH and relocation to Am Bonner Bogen 2 (24.09.2010); according to the company, introduction of the world's first CE-approved DCB.
- 2017
Registration of a participation in France (15.02.2017); Marina Izzo becomes managing director.
- 2019
Xiaojie Chen becomes managing director (12.09.2019); amendment of the articles of association.
- 2022
Miquel Craven-Bartle Capella becomes managing director (15.07.2022).
- 2024
Revenue €21.58 million, 23 employees, annual result €2.25 million.